Cargando…

Applying Desirability of Outcome Ranking End Point to Randomized Trial of Sulopenem for the Treatment of Complicated Urinary Tract Infections

Detalles Bibliográficos
Autores principales:	Dunne, Michael W, Aronin, Steven I, Das, Anita F, Gupta, Jayanti, Akinapelli, Karthik, Breen, Jeanne, Zelasky, Michael T, Puttagunta, Sailaja
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10273356/ https://www.ncbi.nlm.nih.gov/pubmed/36949581 http://dx.doi.org/10.1093/cid/ciad149

Ejemplares similares

Sulopenem for the Treatment of Complicated Urinary Tract Infections Including Pyelonephritis: A Phase 3, Randomized Trial
por: Dunne, Michael W, et al.
Publicado: (2022)

Applying Desirability of Outcome Ranking End Points
por: Dunne, Michael W, et al.
Publicado: (2023)

Sulopenem or Ciprofloxacin for the Treatment of Uncomplicated Urinary Tract Infections in Women: A Phase 3, Randomized Trial
por: Dunne, Michael W, et al.
Publicado: (2022)

2106. Desirability of Outcome Ranking (DOOR): Application to a Phase 3 Registrational Trial Evaluating Sulopenem for Patients with Complicated Intra-abdominal Infection (cIAI)
por: Aronin, Steven I, et al.
Publicado: (2023)

LB-1. Efficacy and Safety of Oral Sulopenem Etzadroxil/Probenecid Versus Oral Ciprofloxacin in the Treatment of Uncomplicated Urinary Tract Infections (uUTI) in Adult Women: Results from the SURE-1 Trial
por: Dunne, Michael W, et al.
Publicado: (2020)

1363. Sulopenem Activity Against Enterobacteriaceae Isolates From Patients With Urinary Tract Infection or Intra-Abdominal Infection
por: Puttagunta, Sailaja, et al.
Publicado: (2018)

1393. A Phase 1, Randomized, Open-Label, Crossover Study in Healthy Subjects Under Fasting Conditions of Orally Administered Sulopenem Etzadroxil Alone or with Probenecid to Determine the Pharmacokinetics of Sulopenem
por: Dunne, Michael, et al.
Publicado: (2018)

1724. Murine Efficacy Studies of Sulopenem Against Bacillus anthracis
por: Puttagunta, Sailaja, et al.
Publicado: (2022)

Sulopenem Disk Development, Quality Control Range, and MIC to Disk Result Correlation for Enterobacterales Isolates
por: Puttagunta, Sailaja, et al.
Publicado: (2023)

1232. Efficacy and Safety of Intravenous Sulopenem Followed by Oral Sulopenem etzadroxil/Probenecid Versus Intravenous Ertapenem Followed by Oral Ciprofloxacin or Amoxicillin-clavulanate in the Treatment of Complicated Urinary Tract Infections (cUTI): Results from the SURE-2 Trial
por: Dunne, Michael W, et al.
Publicado: (2020)

In vitro activity of sulopenem and comparator agents against Enterobacterales and anaerobic clinical isolates collected during the SENTRY Antimicrobial Surveillance Program
por: Maher, Joshua M, et al.
Publicado: (2023)

2569. Pharmacokinetic-Pharmacodynamic Evaluation of Sulopenem Using a Five-Day Hollow-Fiber In Vitro Infection Model
por: VanScoy, Brian D, et al.
Publicado: (2023)

2568. Characterization of Sulopenem Pharmacokinetics-Pharmacodynamics Using a One-Compartment In Vitro Infection Model
por: VanScoy, Brian D, et al.
Publicado: (2023)

Impact of Empirical Antibiotic Therapy on Outcomes of Outpatient Urinary Tract Infection Due to Nonsusceptible Enterobacterales
por: Dunne, Michael W., et al.
Publicado: (2022)

Necrotizing Fasciitis Within 72 hours After Presentation with Skin and Skin Structure Infection
por: Rappo, Urania, et al.
Publicado: (2020)

1527. The Prevalence of Enterobacteriaceae (ENT) Resistant to All Major Classes of Oral Antibiotics from Outpatient Urine Cultures in the United States and Effect on Clinical Outcomes
por: Dunne, Michael, et al.
Publicado: (2018)

Treatment of acute bacterial skin and skin structure infection with single-dose dalbavancin in persons who inject drugs
por: Gonzalez, Pedro Luis, et al.
Publicado: (2018)

Outcomes in Patients with Staphylococcus aureus Bacteremia Treated with Dalbavancin in Clinical Trials
por: Gonzalez, Pedro L., et al.
Publicado: (2021)

A Randomized Clinical Trial of Single-Dose Versus Weekly Dalbavancin for Treatment of Acute Bacterial Skin and Skin Structure Infection
por: Dunne, Michael W., et al.
Publicado: (2016)

Correction to: Sulopenem or Ciprofloxacin for the Treatment of Uncomplicated Urinary Tract Infections in Women: A Phase 3, Randomized Trial
Publicado: (2023)

Safety of Dalbavancin in the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI): Nephrotoxicity Rates Compared with Vancomycin: A Post Hoc Analysis of Three Clinical Trials
por: Gonzalez, Pedro L., et al.
Publicado: (2021)

267 Dalbavancin for the treatment of Streptococcal Skin Infections
por: Puttagunta, Sailaja, et al.
Publicado: (2014)

Use of vancomycin as a surrogate for dalbavancin in vitro susceptibility testing: results from the DISCOVER studies
por: Dunne, Michael W, et al.
Publicado: (2015)

1572. Combination Cefuroxime and Sulopenem is active in vitro against Mycobacterium abscessus
por: Dousa, Khalid M, et al.
Publicado: (2020)

Ranking, selecting, and prioritising genes with desirability functions
por: Lazic, Stanley E.
Publicado: (2015)

675 Outcomes of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) by vancomycin dosing regimen and vancomycin trough serum concentrations in the DISCOVER Program
por: Puttagunta, Sailaja, et al.
Publicado: (2014)

266 Dalbavancin vs Vancomycin for the treatment of acute bacterial skin and skin structure infections (ABSSSI): a subanalysis from the DISCOVER studies
por: Puttagunta, Sailaja, et al.
Publicado: (2014)

Safety of Dalbavancin in the Treatment of Skin and Skin Structure Infections: A Pooled Analysis of Randomized, Comparative Studies
por: Dunne, Michael W., et al.
Publicado: (2015)

Pharmacokinetics, Safety, and Tolerability of a Single 500-mg or 1000-mg Intravenous Dose of Dalbavancin in Healthy Japanese Subjects
por: Scoble, Patrick J., et al.
Publicado: (2015)

Epithelial Lining Fluid and Plasma Concentrations of Dalbavancin in Healthy Adults after a Single 1,500-Milligram Infusion
por: Rappo, Urania, et al.
Publicado: (2019)

A multicenter analysis of trends in resistance in urinary Enterobacterales isolates from ambulatory patients in the United States: 2011–2020
por: Dunne, Michael W., et al.
Publicado: (2022)

1005. The Antibiotic Optimization DOOR: Refining Assessment of Antibiotic Therapy with Desirability of Outcome Ranking
por: Smoke, Steven, et al.
Publicado: (2019)

2905. Development of a Desirability of Outcome Ranking (DOOR) for Skin Infection Clinical Trials
por: Miller, Loren G, et al.
Publicado: (2023)

369. The DOOR is open: A Web-based Application for Analyzing the Desirability of Outcome Ranking
por: Hamasaki, Toshimitsu, et al.
Publicado: (2023)

Correction to: In vitro activity of sulopenem and comparator agents against Enterobacterales and anaerobic clinical isolates collected during the SENTRY Antimicrobial Surveillance Program
Publicado: (2023)

Diagnostic regimes for urinary tract infection--are research results applied to practice?
por: Crawford, V. L., et al.
Publicado: (1995)

Applying Diagnostic Stewardship to Proactively Optimize the Management of Urinary Tract Infections
por: Morado, Faiza, et al.
Publicado: (2022)

What Sexual Behaviors Relate to Decreased Sexual Desire in Women? A Review and Proposal for End Points in Treatment Trials for Hypoactive Sexual Desire Disorder
por: Pyke, Robert, et al.
Publicado: (2016)

The adaptation of the desirability of outcome ranking for interventional clinical trials in epilepsy: A novel consumer‐led outcome measure
por: Vivash, Lucy, et al.
Publicado: (2023)

Cellular Senescence in Renal and Urinary Tract Disorders
por: Santin, Yohan, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_2n97ooh7ql5a7cslc92qh75085